IVA

Inventiva ADR

Oct 21 • 04:00PM ET

5.19

+0.05 0.97 %

Healthcare • Biotechnology • France • NASD

Peers: BMRN VRTX CRSP EDIT PFE NTLA SGMO ABBV GILD NBIX

Index	-	P/E	-	EPS (ttm)	-4.08	Insider Own	1.05%	Shs Outstand	139.11M	Perf Week	4.64%
Market Cap	721.98M	Forward P/E	-	EPS next Y	-1.33	Insider Trans	0.00%	Shs Float	137.64M	Perf Month	-13.79%
Enterprise Value	645.74M	PEG	-	EPS next Q	-0.29	Inst Own	2.49%	Short Float	0.04%	Perf Quarter	56.33%
Income	-338.43M	P/S	48.85	EPS this Y	51.49%	Inst Trans	7.87%	Short Ratio	0.70	Perf Half Y	45.79%
Sales	14.78M	P/B	-	EPS next Y	17.59%	ROA	-269.13%	Short Interest	0.05M	Perf YTD	142.52%
Book/sh	-0.08	P/C	5.04	EPS next 5Y	24.61%	ROE	-	52W High	6.55 -20.73%	Perf Year	114.46%
Cash/sh	1.03	P/FCF	-	EPS past 3/5Y	-30.56% -18.31%	ROIC	-682.34%	52W Low	2.11 145.83%	Perf 3Y	-26.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	26.14% 4.90%	Gross Margin	74.70%	Volatility	10.34% 7.95%	Perf 5Y	-54.67%
Dividend TTM	-	EV/Sales	43.69	EPS Y/Y TTM	-82.84%	Oper. Margin	-745.05%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.95	Sales Y/Y TTM	-12.52%	Profit Margin	-2290.25%	RSI (14)	48.34	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.95	EPS Q/Q	-	SMA20	-5.85%	Beta	0.71	Target Price	17.95
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-1.86%	Rel Volume	1.23	Prev Close	5.14
Employees	119	LT Debt/Eq	-	Earnings	Sep 29 BMO	SMA200	43.36%	Avg Volume	73.87K	Price	5.19
IPO	Jul 10, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-204.49% -0.20%	Trades		Volume	90,985	Change	0.97%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Resumed	H.C. Wainwright	Buy	$20
Aug-27-25	Initiated	Piper Sandler	Overweight	$26
Feb-21-25	Initiated	TD Cowen	Buy	$10
Nov-12-24	Initiated	UBS	Neutral	$3
Oct-27-23	Initiated	Canaccord Genuity	Buy	$12
May-31-23	Initiated	ROTH MKM	Buy	$11
May-19-23	Upgrade	Societe Generale	Sell → Buy
Mar-17-23	Initiated	Stifel	Buy	$27
Nov-15-22	Downgrade	Societe Generale	Buy → Sell
Mar-08-21	Downgrade	Societe Generale	Buy → Sell
Aug-05-20	Initiated	ROTH Capital	Buy
Aug-04-20	Initiated	Stifel	Buy	$18
Aug-04-20	Initiated	Guggenheim	Buy	$26

Show Previous Ratings

Sep-26-25 09:55AM	Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-29-25 09:55AM	How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79% (Zacks)
Aug-11-25 04:00PM	Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-31-25 04:00PM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jul-29-25 04:00PM	Inventiva Reports Preliminary 2025 First-Half Financial Information¹ (GlobeNewswire)
04:05PM	Loading…
Jul-09-25 04:05PM	Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance (GlobeNewswire)
Jul-07-25 04:00PM	Inventiva receives $10 million milestone payment from CTTQ (GlobeNewswire) +14.57%
Jul-02-25 04:00PM	Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease (GlobeNewswire)
Jun-24-25 03:51PM	Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target (Insider Monkey) -7.94%
Jun-10-25 04:00PM	Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors (GlobeNewswire)
Jun-03-25 12:00PM	Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +6.78%
May-27-25 04:00PM	Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference (GlobeNewswire) +8.59%
May-23-25 02:30AM	Inventiva reports 2025 First Quarter Financial Information¹ (GlobeNewswire)
02:00AM	Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 (GlobeNewswire)
May-22-25 08:00AM	Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux (GlobeNewswire)
02:30AM	Loading…
May-05-25 02:30AM	Inventiva secures the 116 million second tranche of its structured financing of up to 348 million (GlobeNewswire)
Apr-30-25 04:00PM	Statement of total voting rights and shares forming the companys share capital as of April 11, 2025 (GlobeNewswire) -5.41%
04:00PM	Combined General Meeting of May 22, 2025 - Availability of the preparatory documents (GlobeNewswire)
Apr-24-25 04:01PM	Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor (GlobeNewswire)
Apr-15-25 04:00PM	Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F (GlobeNewswire)
Apr-04-25 09:40AM	Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-01-25 05:00PM	Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis (GlobeNewswire) +5.44%
Mar-27-25 10:50AM	Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript (SeekingAlpha) +5.86%
Mar-26-25 04:00PM	Inventiva reports its 2024 full year results and provides a business update (GlobeNewswire)
Mar-19-25 04:00PM	Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results (GlobeNewswire)
Feb-26-25 04:00PM	Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment (GlobeNewswire)
Feb-20-25 04:00PM	Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial (GlobeNewswire)
Feb-10-25 04:00PM	Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update (GlobeNewswire) -5.71%
Jan-29-25 04:00PM	Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology (GlobeNewswire) +5.22%
Jan-24-25 04:00PM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux (GlobeNewswire) -7.54%
04:00PM	Loading…
Jan-22-25 04:00PM	Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 (GlobeNewswire) +16.13%
Dec-17-24 04:00PM	Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 02:30AM	Inventiva secures 21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to 348 million (GlobeNewswire)
Dec-12-24 04:00PM	Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024 (GlobeNewswire)
Nov-21-24 04:00PM	Inventiva reports 2024 Third Quarter Financial Information (GlobeNewswire)
Nov-20-24 04:00PM	Statement of total voting rights and shares forming the companys share capital as of November 4, 2024 (GlobeNewswire)
04:00PM	Combined General Meeting of December 11, 2024 - Availability of the preparatory documents (GlobeNewswire)
Nov-15-24 04:00PM	Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting late-breaker session (GlobeNewswire)
Oct-30-24 04:00PM	Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH (GlobeNewswire)
Oct-21-24 08:30AM	Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-14-24 01:45PM	Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants (GlobeNewswire) +41.27%
02:35AM	Inventiva announces Filing of 2024 Half-Year Report Conditions for Accessing or Consulting the Report (GlobeNewswire)
02:30AM	Inventiva announces financing of up to 348 million to advance the NATiV3 Phase 3 MASH study (GlobeNewswire)
Sep-25-24 04:00PM	Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results (GlobeNewswire) -17.32%
Jul-31-24 04:00PM	Inventiva Reports Preliminary 2024 First-Half Financial Information (GlobeNewswire)
Jul-25-24 04:00PM	Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor (GlobeNewswire)
Jul-19-24 11:30AM	Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jul-18-24 02:30AM	Inventiva announces a 20.1 million issuance of royalty certificates (GlobeNewswire)
Jul-05-24 04:00PM	Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position (GlobeNewswire) -10.85%
Jun-21-24 04:05PM	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 (GlobeNewswire) -8.25%
04:00PM	Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024 (GlobeNewswire)
Jun-18-24 09:35AM	Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) (Zacks)
May-30-24 02:30AM	Statement of total voting rights and shares forming the companys share capital as of May 13, 2024 (GlobeNewswire)
02:30AM	Combined General Meeting of June 20, 2024 - Availability of the preparatory documents (GlobeNewswire)
May-22-24 04:00PM	Inventiva announces two scientific presentations at the EASL International Liver Congress 2024 (GlobeNewswire)
May-21-24 04:00PM	Inventiva reports 2024 First Quarter Financial Information and provides a corporate update (GlobeNewswire)
May-16-24 04:00PM	Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH (GlobeNewswire)
May-13-24 04:08PM	Why Is Inventiva's Stock Trading Higher on Monday? (Benzinga) +5.33%
02:30AM	Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor (GlobeNewswire)
Apr-03-24 04:00PM	Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F (GlobeNewswire)
Apr-01-24 02:17PM	Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 03:00AM	Inventiva announces the nomination of Andre Turenne as Director (GlobeNewswire) -5.24%
Mar-27-24 04:00PM	Inventiva reports its 2023 full-year results (GlobeNewswire)
Mar-22-24 04:00PM	Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results (GlobeNewswire)
Mar-18-24 04:00PM	Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D (GlobeNewswire) -20.87%
Mar-13-24 04:00PM	Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D (GlobeNewswire)
Mar-07-24 04:00PM	Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed (GlobeNewswire) +6.77%
Feb-16-24 05:46AM	Inventiva pauses phase 3 MASH study over patient's raised liver enzymes (FierceBiotech.com) -15.99%
Feb-15-24 04:35PM	Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3 (GlobeNewswire)
Jan-24-24 04:15PM	Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jan-10-24 04:00PM	Inventiva draws down the second tranche of 25 million under existing Finance Contract with the European Investment Bank (GlobeNewswire)
Dec-20-23 04:00PM	Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program (GlobeNewswire) -5.62%
Dec-04-23 04:05PM	Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH (GlobeNewswire)
Nov-21-23 04:00PM	Inventiva reports 2023 Third Quarter Financial Information (GlobeNewswire)
Nov-06-23 04:00PM	Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting 2023 (GlobeNewswire) +6.22%
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
Sep-28-23 04:00PM	Inventiva reports its 2023 first-half financial results and provides a corporate update (GlobeNewswire)
Sep-20-23 04:00PM	Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (GlobeNewswire) +9.40%
Aug-31-23 01:30AM	Inventiva announces a financing of approximately 35.7 million from new and existing investors, consisting of a 30.6 million reserved capital increase and a 5.1 million issuance of royalty certificates (GlobeNewswire)
Jul-27-23 04:33PM	Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update (GlobeNewswire)
04:00PM	Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update (GlobeNewswire)
Jun-24-23 02:00AM	Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association (GlobeNewswire)
Jun-13-23 05:00PM	Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD (GlobeNewswire) +6.54%
Jun-08-23 02:30AM	Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients (GlobeNewswire) -5.29%
Jun-07-23 04:00PM	Inventiva announces five scientific presentations at the EASL International Liver Congress 2023 (GlobeNewswire)
May-26-23 04:00PM	Results of the votes of the Combined Shareholders General Meeting of May 25, 2023 (GlobeNewswire) +7.45%
May-25-23 04:00PM	Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China (GlobeNewswire) -6.00%
09:50AM	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023 (GlobeNewswire)
May-16-23 04:00PM	Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update (GlobeNewswire) -5.56%
May-04-23 02:31AM	Statement of total voting rights and shares forming the companys share capital as of April 17, 2023 (GlobeNewswire) +11.58%
02:30AM	Combined General Meeting of May 25, 2023. Availability of the preparatory documents (GlobeNewswire)
Apr-09-23 07:34PM	Inventiva S.A. (NASDAQ:IVA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 08:19AM	Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F (GlobeNewswire) -7.71%
Mar-29-23 04:00PM	Inventiva reports its 2022 full-year results (GlobeNewswire)
Mar-23-23 05:00PM	Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results (GlobeNewswire)
Feb-14-23 05:00PM	Correction: Inventiva reports preliminary financial results for Full-Year 2022¹ (GlobeNewswire)
04:00PM	Inventiva reports preliminary financial results for Full-Year 2022¹ (GlobeNewswire)
Jan-30-23 04:00PM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jan-26-23 02:00AM	Results of the votes of the Combined Shareholders General Meeting of January 25, 2023 (GlobeNewswire)
Jan-04-23 04:00PM	Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis (GlobeNewswire) -7.84%

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frederic Cren on October 27, 2011 and is headquartered in Daix, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IVA

Inventiva ADR

Upgrade your FINVIZ experience